Jasmine Sun

Jasmine Sun appears in The ‘biohacking’ trend that has tech workers experimenting on themselves as the independent technology journalist whose New York Times reporting grounds Marketplace Tech’s episode on Silicon Valley peptide use. Her interview connects cheaper GLP-1 Agonists, Ozempic demand, research-chemical labeling, Chinese peptide suppliers, and founder-style risk tolerance into a single Tech-Culture Biohacking story.

Her contribution is mainly explanatory. She distinguishes legal permissibility from medical assurance: a substance may be outside the DEA-controlled-drug list while still lacking FDA approval, known contents, clean manufacturing standards, human clinical evidence, or safe dosing context.

Connections

• Marketplace Tech - show that interviews her.
• New York Times - publication context for the underlying reporting.
• Gray-Market Peptides, Research Chemical Loophole, and GLP-1 Agonists - main topics she explains.
• Tech-Culture Biohacking and Self-Experimentation - cultural and behavioral frame she gives the trend.